Review

Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer

Jonathan Thomas 1,2 and Guru Sonpavde 1,*

1 Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; jdthomas@bidmc.harvard.edu
2 Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
* Correspondence: gurup_sonpavde@dfci.harvard.edu

Simple Summary: In recent years, there have been several advances in the care of advanced bladder cancer, highlighted by the addition of immune checkpoint inhibitors to the care of advanced disease. Despite these advances, there is a need for further improvement; the morbidity and mortality associated with advanced bladder cancer remain high. With the recent incorporation of advanced molecular techniques, there is more clarity regarding key genetic alterations of the disease. Therapies directed at specific genetic aberrations in bladder cancer provide both proven and potential paths forward. This review discusses the key targetable genetic aberrations and summarizes the current status of targeted therapies in muscle-invasive bladder cancer.

Abstract: Despite the introduction of immune checkpoint inhibitors and antibody–drug conjugates to the management of advanced urothelial carcinoma, the disease is generally incurable. The increasing incorporation of next-generation sequencing of tumor tissue into the characterization of bladder cancer has led to a better understanding of the somatic genetic aberrations potentially involved in its pathogenesis. Genetic alterations have been observed in kinases, such as FGFRs, ErbBs, PI3K/Akt/mTOR, and Ras-MAPK, and genetic alterations in critical cellular processes, such as chromatin remodeling, cell cycle regulation, and DNA damage repair. However, activating mutations or fusions of FGFR2 and FGFR3 remains the only validated therapeutically actionable alteration, with erdafitinib as the only targeted agent currently approved for this group. Bladder cancer is characterized by genomic heterogeneity and a high tumor mutation burden. This review highlights the potential relevance of aberrations and discusses the current status of targeted therapies directed at them.

Keywords: muscle-invasive bladder cancer; gene fusions; targeted therapy; fibroblast growth factor receptor; erdafitinib; ErbBreceptor; PI3K; Akt; mTOR; MAPK; chromatin remodeling; cell cycle regulation; DNA damage repair

1. Introduction

Urothelial carcinoma includes tumors of the bladder as well as the renal pelvis and ureters. Bladder cancer is the location of around 90% of urothelial carcinoma (UC) [1]. It is the tenth most common cancer worldwide [2]. There are approximately 570,000 new cases of bladder cancer diagnosed annually, with a male-to-female ratio of 4:1 [2]. In the United States, there are 81,000 new cases and 17,000 deaths from bladder cancer projected for 2022 [3].

Advanced or metastatic bladder cancer represents 4% of newly diagnosed bladder cancer. The vast majority of new cases (~75%) have non-muscle-invasive disease. However, among those who present with initially muscle-invasive bladder-confined disease, ~50% progress to metastatic disease [1]. In advanced or metastatic disease, first-line treatment...
with cisplatin-based chemotherapy has a median overall survival of ~15 months, while those who are cisplatin-ineligible have suboptimal outcomes (~9 months) [4,5]. Recent advances have seen the addition of programmed cell death protein 1/programmed cell death ligand 1 (PD1/L1) inhibitors in the management of metastatic disease in patients who are post-platinum or cisplatin/platinum-ineligible [6–9]. Despite these advancements, the objective response rate with PD1/L1 inhibitors is 21–27%, and the median survival is 8–11 months [6,9]. PD1/L1 inhibitors are also being used as maintenance therapy following platinum-based therapy in patients with responding or stable disease [10]. In addition, antibody–drug conjugates (ADCs), enfortumab vedotin (EV), and sacituzumab grovitecan (SG) have emerged as valuable additions to the therapeutic armamentarium [11–13]. Despite these advances, metastatic disease is generally incurable.

As next-generation genomics technologies are being employed, additional potentially targetable pathways are being revealed [14–16]. Erdafitinib, which targets the family of fibroblast growth factor (FGFR) tyrosine kinase receptors, is the first targeted therapy to be FDA-approved for the treatment of advanced urothelial carcinoma following platinum-based chemotherapy and harboring activating mutations or fusions in FGFR2 or FGFR3 [17]. In addition to the FGFRs, several other potentially targetable genetic alterations involving a variety of cellular functions have been implicated in bladder cancer, including the ErbB receptors, the PI3K/Akt/mTOR pathway, the RAS-MAPK signaling pathway, chromatin remodeling, cell cycle regulation, and DNA damage repair (Figure 1). In this review, we summarize the potentially actionable somatic genomic alterations in muscle-invasive and advanced urothelial carcinoma and highlight ongoing efforts to develop therapeutics directed at these alterations.

As next-generation genomics technologies are being employed, additional potentially targetable pathways are being revealed [14–16]. Erdafitinib, which targets the family of fibroblast growth factor (FGFR) tyrosine kinase receptors, is the first targeted therapy to be FDA-approved for the treatment of advanced urothelial carcinoma following platinum-based chemotherapy and harboring activating mutations or fusions in FGFR2 or FGFR3 [17]. In addition to the FGFRs, several other potentially targetable genetic alterations involving a variety of cellular functions have been implicated in bladder cancer, including the ErbB receptors, the PI3K/Akt/mTOR pathway, the RAS-MAPK signaling pathway, chromatin remodeling, cell cycle regulation, and DNA damage repair (Figure 1). In this review, we summarize the potentially actionable somatic genomic alterations in muscle-invasive and advanced urothelial carcinoma and highlight ongoing efforts to develop therapeutics directed at these alterations.

![Figure 1](image_url). Potentially targetable genetically altered pathways in advanced bladder cancer. Frequently mutated pathways in advanced bladder cancer include RTKs such as the FGFRs and ErbB receptor groups. Intracellular pathways include the PI3K/Akt/mTOR pathway, the RAS-MAPK signaling pathway, chromatin remodeling, and cell cycle regulation. Significant crosstalk exists between the PI3K/Akt/mTOR and RAS-MAPK pathways. Downstream effects of mTOR activation include cell cycle progression and cellular growth; downstream effects of MAPK activation include the regulation of translation, differentiation, and the cell cycle. Figure created with biorender.com (accessed on 22 February 2022).
2. FGFRs

There are four fibroblast growth factor receptors (FGFR1–4) [18]. FGFRs are tyrosine kinase receptors that bind at least 18 fibroblast growth factors (FGFs). Once binding fibroblast growth factors, the FGFRs dimerize and become activated via phosphorylation of their cytoplasmic domains [19–21]. Activation leads to signaling via a variety of pathways including PLCγ1, RAS-MAPK, PI3K, and STATs [22]. These pathways regulate many functions including cellular migration, proliferation, and differentiation [22].

FGFR3 dysregulation via mutation, overexpression, or both have been noted in 54% of invasive urothelial carcinomas (UCs) [23]. Interestingly, mutations in FGFR3 are more frequent (~80%) in non-invasive UCs and in upper tract UC (~1/3), which are enriched for luminal papillary gene expression subtype tumors with poor immune infiltration [14–16]. Meanwhile, FGFR3 mutations have been implicated in 5–20% of muscle-invasive bladder cancer (MIBC) [14,23,24]. These aberrations are commonly point mutations in the extracellular region leading to ligand-independent dimerization, activation, and signaling [15,25,26]. Invasive tumors are more likely to have upregulation of wild-type FGFR3 [15]. Overexpression of the wild-type FGFR3 may lead to ligand-independent dimerization and activation [15]. Ligand-dependent mechanisms via increased levels of fibroblast growth factors may also contribute to tumor development, although the therapeutic actionability is unclear [27].

FGFR3-TACC gene fusions are also relevant to MIBC and were identified more frequently in younger patients, never smokers and those with Asian ethnicity [28]. TACC3 is involved in the stability and organization of the mitotic spindle [29]. FGFR3-TACC3 fusions are formed via tandem duplications on chromosome 4p16 [30]. FGFR3-TACC3 fusions are relatively rare, with a frequency of 2–3% in MIBC [31–33]. Regarding pathogenesis of the fusion, in glioblastoma, the FGFR3-TACC3 fusion has been shown to lose a regulatory site for miR-99a, an inhibitor of FGFR3, leading to enhanced expression of the gene fusion [30]. Furthermore, a coiled-coil domain on TACC3 increases the activity of FGFR3 via phosphorylation of its tyrosine kinase domains [34]. The FGFR3-TACC3 fusion also results in alterations of TACC3 function, which can result in mitotic defects and aneuploidy [35–37].

FGFR1 aberrations have been less frequently studied than FGFR3. The prevalence of FGFR1 genomic alterations was noted to be 7–14% [32,38]. FGFR1 and subsequent MAPK activation have been noted to promote proliferation and survival as well as induce epithelial-to-mesenchymal transition (EMT) [39,40].

Resistance to FGFR inhibition can develop due to upregulation of bypass pathways, such as PI3K-AKT, RAS-MAPK, and STAT [41]. Gatekeeper mutations of the FGFR binding domain have also been associated with resistance, e.g., FGFR1 V561M, FGFR2 V564F/I, FGFR3 V555M, and FGFR4 V550E/L [41–44]. Specific FGFR inhibitors may target these gatekeeper mutations; e.g., Debio 1347 was effective against FGFR2 V564I, and futibatinib was active in FGFR inhibitor refractory patients [45,46].

2.1. First-Generation FGFR Inhibitors

While the individual mechanisms of actions are nuanced beyond the scope of this article, the majority of FGFR inhibitors listed function by binding near the adenine-binding site of the receptor tyrosine kinase [47]. First-generation and promiscuous FGFR tyrosine kinase inhibitors have been evaluated as monotherapy or in combination with cisplatin-based chemotherapy or PD1 inhibition in unselected patients, e.g., dovitinib, nintedanib, and lenvatinib [48–50]. Nintedanib did not improve pathologic complete response in combination with neoadjuvant cisplatin-based combination; however, there was an improvement in PFS and OS [49]. Lenvatinib inhibits VEGFRs in addition to FGFRs and has demonstrated promising activity in combination with pembrolizumab as first-line therapy in unselected patients, which led to an ongoing phase III trial comparing pembrolizumab vs. lenvatinib plus pembrolizumab in platinum-ineligible or cisplatin-ineligible patients with PD-L1 high-expressing tumors (NCT03898180) [50].
2.2. Erdafitinib

Several potent and FGFR-specific second-generation therapeutics have been developed. Erdafitinib is an orally bioavailable selective and potent inhibitor of FGFR1–4 [17]. Erdafitinib was evaluated in an open-label, single-arm, phase II trial of 99 patients with locally advanced and unresectable or metastatic urothelial carcinoma with FGFR2 or 3 mutations or fusions who had progressed on prior platinum-based chemotherapy [51,52]. Notably, the dose of erdafitinib was guided by off-cancer on-target induction of hyperphosphatemia by inhibition of FGFR1. Those with an absence of hyperphosphatemia ≥5.5 nmol/L at ~2 weeks were dose-escalated to 9 mg once daily in the absence of other prohibitive toxicities. The primary endpoint of objective response rate (ORR) was achieved in 40% of patients (3% complete, 37% partial). The median progression-free survival (PFS) was 5.5 months, and the median overall survival (OS) was 11.3 months after a median follow-up of 24 months [52]. The response rate was not affected by visceral metastasis. The ORR appeared higher in those with FGFR mutations vs. fusions (49% and 16%, respectively). EGFR, CCND1, and BRAF alterations in baseline ctDNA were associated with poor outcomes. Common grade 3 or 4 toxicities included hyponatremia (11%), stomatitis (10%), and asthenia (7%). Notable FGFR-inhibitor class-specific toxicities included hyperphosphatemia, which was present in 77% of patients, and ocular toxicities (10% with grade 3 or higher), such as retinal pigment detachment or central serous retinopathy. Based on this trial, erdafitinib was granted accelerated FDA approval in April 2019 for the treatment of locally advanced or metastatic urothelial carcinoma with FGFR2 or FGFR3 genomic alterations that have progressed on platinum-based chemotherapy.

Since erdafitinib’s FDA approval, it remains unclear what the appropriate sequence of second-line therapies is between immune checkpoint inhibitors or erdafitinib in those with FGFR-activating alterations [53]. FGFR-altered UC has been suggested to be less likely to respond to immunotherapy, due to reduced T-cell infiltration in FGFR-altered UC [54]. Indeed, in the above phase II trial that evaluated erdafitinib, of 19 patients who received a PD1/L1 inhibitor previously, only one responded. However, another retrospective study assessing response rates in relation to FGFR3 mutation status, including two key immunotherapy trials (IMVigor 210 and CheckMate 275) that administered post-platinum atezolizumab or nivolumab, noted similar response rates in patients with and without FGFR3 mutations [16,53,55]. The association of FGFR3-mutant UC with lower T-cell infiltration may be counteracted by lower stromal transforming growth factor (TGF)–β, which is a driver of epithelial–mesenchymal transition and therefore a source of resistance against the activity of PD1/L1 inhibition. Toxicity profiles also differ between immunotherapy and FGFR inhibition. There is a current randomized phase III trial comparing the benefit of erdafitinib versus PD1/L1 inhibitor immunotherapy or chemotherapy in metastatic or surgically unresectable UC with progression following prior therapy (NCT03390504) (see Table 1). In addition, there is an ongoing randomized phase II trial comparing erdafitinib alone vs. erdafitinib with anti-PD-L1 therapy (cetrelimab) as first-line therapy in patients with metastatic UC who are cisplatin-ineligible (NCT03473743). Preliminary results on interim analysis showed a promising increase in ORR with combination therapy, and accrual continues [56].
| Drug Name | Phase | Setting | FGFR Status | Intervention | # of Pts | Status | NCT # |
|-----------|-------|---------|-------------|--------------|----------|--------|-------|
| AZD4547  | Ib    | Metastatic, 2nd or 3rd line | FGFR1–4 GA | AZD4547, AZD4547 + durvalumab | 156 | Active, not recruiting | 02546661 |
|           | II    | Metastatic, progression through standard therapy | FGFR1–3 mutation/ translocation | AZD4547 | 6452 | Recruiting | 02465060 * |
| Derazantinib | I/II  | Advanced/Metastatic | FGFR1/2/3 GA | derazantinib vs. derazantinib + atezolizumab (multiple subgroups for first vs. second line as well as derazantinib dosing) | 272 | Recruiting | 04045613 |
| Erdfatinib | Ib    | Metastatic, progression on platinum and PD1/L1 | FGFR2/3 GA | erdfatinib + enfortumab vedotin | 30 | Recruiting | 04963153 |
|           | II    | Metastatic, progression through standard therapy | FGFR amp, mutation, or fusion | erdfatinib | 6452 | Recruiting | 02465060 * |
|           | I/II  | Advanced/Metastatic | Not required | erdfatinib vs. erdfatinib + cetrelimab | 126 | Recruiting | 03473274 |
|           | II    | Metastatic | Not required | erdfatinib (intermittent vs. continuous dosing) | 236 | Recruiting | 02365957 |
|           | III   | Advanced/Metastatic | FGFR2/3 GA | erdfatinib vs. vinflunine or docetaxel vs. pembrolizumab | 631 | Recruiting | 03390504 |
| Pemigatinib | II    | Adjuvant, pT3–4 or pN1–3 | pemigatinib | pembrolizumab vs. placebo | 2 | Active, not recruiting | 04294277 |
|           | II    | Advanced/Metastatic, progressed on first line | FGFR1–4 GAs | pemigatinib intermittent dose vs. pemigatinib continuous dose | 263 | Active, not recruiting | 02872714 |
| Regorafenib | II    | Progression on all standard therapies | FGFR 1–4 GA | regorafenib | 160 | Recruiting | 02795156 |
| Rogaratinib | Ib/II | Advanced/Metastatic—first line, cisplatin-ineligible | High FGFR1/3 mRNA levels | rogaratinib + atezolizumab vs. atezolizumab | 210 | Active, not recruiting | 03473756 |

* Trial with additional treatment arms not mentioned in the table. Abbreviations: GA, Genomic Alterations; FGFR, Fibroblast Growth Factor Receptor; NCT, National Clinical Trial.
2.3. Investigational Specific FGFR Inhibitors

In addition to erdafitinib, several other inhibitors of FGFRs are being evaluated. Roga-
ratinib, an FGFR1–4 inhibitor, was evaluated in an open-label, randomized, phase II/III
study comparing rogaratinib with chemotherapy (docetaxel, paclitaxel, or vinflunine) in lo-
cally advanced or metastatic UC patients who had received platinum-based chemotherapy
and had tumors overexpressing FGFR1 or 3 mRNA (NCT03410693) [57]. Unfortunately,
the trial was stopped early due to futility for improved outcomes with rogaratinib. Sim-
ilar overall response rates were noted with rogaratinib versus standard chemotherapy
(19.5%/19.3%, respectively). Grade 3 or 4 toxicities were present in 47% of patients re-
cieving rogaratinib and 56% of patients receiving chemotherapy. Of note, on subsequent
analysis, the overall response rate was higher in patients with FGFR3 DNA alterations
(52.4% with rogaratinib and 26.7% with chemotherapy), suggesting that selecting patients
based on gene expression may not optimally enrich for tumors driven by FGFR. There is an
ongoing phase Ib/II study of the combination of rogaratinib with atezolizumab in patients
with advanced/metastatic UC who are first-line cisplatin-ineligible and exhibit FGFR gene
overexpression (NCT03473756) [58]. Preliminary results in 26 patients reported a disease
control rate of 83%.

Infigratinib (BGJ398), an orally bioavailable, selective FGFR1–3 inhibitor, was eval-
uated in a single-arm, phase II trial of 67 patients with metastatic UC who had either
progressed on or were intolerant of platinum-based chemotherapy and harbored tumors
FGFR3 genetic alterations [59]. The study noted 64.2% of patients with disease control,
ORR of 25.4%, and a median PFS of 3.75 months. There is an ongoing phase III, double-
blind, randomized, placebo-controlled trial assessing infigratinib in the adjuvant setting in
patients with high-risk muscle-invasive UC at risk for recurrence (NCT04197986). A phase
I trial is evaluating infigratinib in the neoadjuvant setting for cisplatin-ineligible patients
with FGFR3-activating genomic alterations who are candidates for radical cystectomy
(NCT04972253).

Pemigatinib (INCB054828) is a selective inhibitor of FGFR1–3 [60]. Preliminary results
in the metastatic setting demonstrated efficacy with an overall response rate of 25% in a
cohort of 64 patients [61]. There are ongoing phase II trials in two settings in UC: adjuvant
(NCT04294277) and metastatic or surgically unresectable (NCT02872714).

Other investigational small-molecule oral FGFR inhibitors undergoing evaluation
include derazantinib, futibatinib, and AZD4547 (Table 1) [62,63]. In contrast to the combina-
tion of erdafitinib and cetrelimab, the combination of durvalumab and AZD4547 did not ap-
pear to improve efficacy following platinum-based chemotherapy in the biomarker-guided
BISCAY trial [64]. Vofatamab (B-701), a monoclonal antibody that prevents activation of
both wild-type and mutated FGFR3, was evaluated as a single agent or in combination
with docetaxel in a phase Ib/II trial in patients with relapsed or refractory metastatic UC
with FGFR mutations or fusions (NCT02401542) [65]. The ORRs of vofatamab and the
combination were 4.8% and 19.0%, respectively. Vofatamab was also being evaluated in
another phase Ib/II trial in combination with pembrolizumab in metastatic UC in patients
who had progressed on chemotherapy (NCT03123055) [66]. Interestingly, in preliminary
results, the response to vofatamab did not correlate with FGFR3 mutation or fusion (42.9%
with mutation/fusion and 33.3% in FGFR-wildtype patients) [66].

3. ErbB Receptors

The ErbB group of receptor tyrosine kinases (RTKs) is composed of four receptors:
EGFR (ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3), and ErbB-4 (HER4) [67]. ErbB
RTKs are activated by binding EGF-family growth factors via paracrine or autocrine se-
cretion [68]. Ligand binding induces receptor dimerization followed by activation of the
intracellular tyrosine kinase domain. Numerous signal transduction pathways can then be
initiated, including activation of the Ras-MAPK [69,70] or the PIK3CA pathway [71].

Within the ErbB family, mutations or amplifications in EGFR, ErbB-2, and ErbB-3 have
been associated with MIBC [31]. EGFR aberrations are present in 6–14% [31,38,72] of MIBC,
while ErbB-2 mutations are present in 6–23%, and ErbB-3 mutation are present in 6%. Overactivation of ErbB receptors increases activation of signaling pathways, promoting cell proliferation and survival [73]. In addition, ErbB receptor aberrations have been associated with increased chromosome instability [74].

3.1. ErbB1 Receptor Inhibitors

There have been multiple clinical trials of ErbB receptor inhibitors in patients with MIBC. Gefitinib, an EGFR-TKI inhibitor, was evaluated in combination with first-line chemotherapy in patients with advanced or metastatic UC in a phase II trial [75]. There was no significant difference in time to progression in patients randomized to receive gefitinib when compared to chemotherapy alone. Cetuximab, an EGFR-TKI inhibitor, was also evaluated in a phase II trial in patients with advanced UC. There were no improvements in outcomes in patients treated with cetuximab; however, there was an increase in adverse events [76]. Of note, EGFR mutational testing was not performed in patients in either of the trials mentioned above.

3.2. ErbB2 (HER2) Inhibitors

Trastuzumab, a monoclonal antibody targeting ErbB-2, has an established role in gastric and breast cancer. It was evaluated in locally advanced or metastatic UC in a multicenter randomized phase II first-line study [77]. Her2 protein overexpression by immunohistochemistry was a part of the eligibility criteria. Patients were randomized to chemotherapy (gemcitabine with cisplatin or carboplatin) alone or chemotherapy plus trastuzumab. Unfortunately, there was no significant difference in progression-free survival or overall survival. Notably, 563 patients were screened to randomize 61 patients, highlighting the challenges of conducting trials in biomarker-selected patients. Additional trials assessing the effectiveness of trastuzumab are ongoing (Table 2). For example, the “MyPathway” study (NCT02091141) is a multi-basket study, of which one study arm is assessing trastuzumab with pembrolizumab in ErbB-2 positive metastatic urothelial carcinoma [78]. Lapatinib, a tyrosine kinase inhibitor, which inhibits both EGFR and ErbB-2, was evaluated in a phase III trial of patients with metastatic UC and EGFR or Her2 protein expression who had received chemotherapy and did not have progressive disease [79]. Patients were randomly assigned to lapatinib or placebo. The results were disappointing, and there were no improvements in outcomes in patients treated with lapatinib.

While inhibition of Her2 is an established treatment in breast and gastric cancer, inhibition of ErbB receptors has not demonstrated similar effectiveness in MIBC and advanced UC to this date. The trials mentioned above have either not screened for Her2 status or have used FISH and IHC to identify patients overexpressing ErbB2. These studies may not have adequately selected patients who may benefit from ErbB inhibition. Kiss et al. performed a comprehensive analysis of Her2 alterations at the DNA, RNA, and protein level [80]. They reported a significant proportion of ErbB2 amplifications without overexpression of ErbB2. They identified instances of ErbB2 overexpression without amplification of ErbB2. They suggest that gene amplification is not the only factor increasing high ErbB2 expression in MIBC. The presence of single-nucleotide variations (SNVs) in the extracellular domain of the ErbB2 receptor resulted in a lower affinity of antibody binding, which may lead to falsely low levels of expression reported via IHC and may also affect the binding of ErbB2 inhibitors. They also noted that when compared to gastric and breast cancer, bladder cancer has a relatively high rate of genomic alterations including mutations and amplification [31]. The high rate of genomic alterations potentially reduces the likelihood that an individual alteration such as ErbB2 is a significant oncogenic driver even when it is overexpressed. Notably, there were cases in which ErbB2 was overexpressed in the absence of other known oncogenic alterations. In these cases, it is more likely that ErbB2 has oncogenic relevance. All in all, Kiss et al. suggest an algorithm incorporating the presence of IHC for ErbB2 as well as detection of gene amplification for ErbB2, somatic mutations in ErbB2, and the presence of other oncogenic gene amplifications as a more targeted means...
of assessing patients who may benefit from ErbB2 inhibition. Their algorithm requires clinical validation. A more refined targeted approach may improve the outcomes of ErbB inhibitors in MIBC.

### Table 2. Ongoing clinical trials targeting genetic alterations in advanced bladder cancer (not including FGFRs).

| Drug Name | Phase | Setting | Targeted GA | Intervention | #Pts | Status | NCT # |
|-----------|-------|---------|-------------|-------------|------|--------|-------|
| Ado-Trastuzumab | II | Adv/Met UC, Erbb2 GA | Erbb2 | ado-trastuzumab | 135 | Recruiting | 02675829 |
| Afatinib | II | Adv/Met UC, no standard options available | Erbb1 | afatinib | 160 | Recruiting | 02795156 * |
| RC48-ADC | II | Adv/Met UC, cisplatin-refractory ErbB2 overexpression | ErbB2 | RC48-ADC | 60 | Active, not recruiting | 03809013 |
| Tucatinib, Trastuzumab | II | Adv/Met UC, ErbB2 GA | ErbB2 | tucatinib + trastuzumab | 270 | Recruiting | 04579380 |
| **PI3K/Akt/mTOR Pathway** |
| Sapanisertib | II | Adv/Met UC, platinum-refractory, with TSC GA | mTOR | sapanisertib | 209 | Active, not recruiting | 03047213 |
| **Chromatin Remodeling** |
| Belinostat | I | Adv/Met UC, no standard therapy available, ARID1A lof | HDAC | tremelimumab + durvalumab + belinostat | 9 | Recruiting | 05154994 |
| Entinostat | II | MIBC, Neoadjuvant | HDAC | entinostat + pembrolizumab | 20 | Recruiting | 03978624 |
| Tazemetostat | I/II | Adv/Met UC, cisplatin-refractory | EZH2 | tazemetostat + pembrolizumab | 30 | Recruiting | 03854474 |
| Vorinostat | I/Ib | Adv/Met UC, platinum-refractory | HDAC | vorinostat + pembrolizumab | 57 | Active, not recruiting | 02619253 |
| **Cell Cycle Regulation** |
| Trilaciclib | II | Adv/Met UC—first line | CDK4/6 | trilaciclib + platinum chemo then trilaciclib + avelumab | 90 | Recruiting | 04887831 |
| **DNA Damage Repair** |
| Niraparib | I/II | Adv/Met UC, platinum-refractory | DDR, RTKs | niraparib + cabozantinib | 20 | Recruiting | 03425201 |
| Olaparib | II | Adv/Met UC, platinum, or PD1/L1 refractory | DDR | olaparib | 60 | Recruiting | 03375307 |
| II | Adv/Met UC, ARID1A mutated, ATM mutated | DDR, ATM | olaparib + AZD6738 | 68 | Recruiting | 03682289 |
| Talazoparib | II | Adv/Met UC, s/p platinum with stable disease | DDR | talazoparib + avelumab | 50 | Recruiting | 04678362 |
| **Umbrella/Basket/Multi-Arm Trials** |
| BISCAY | Ib | Metastatic UC, 2nd or 3rd line | HRR, CKDN2A, RB1, MAPK, mTOR | olaparib + durvalumab AZD1775 + durvalumab vistusertib + durvalumab | 156 | Active, not recruiting | 02546661 * |
| My Pathway | Ia | Adv/Met UC, Erbb1 or ErbB2 GA | Erbb1, ErbB2, BRAF | trastuzumab + pertuzumab or Erlotinib or vemurafenib + cobimetinib | 676 | Active, not recruiting | 02091141 * |
| The Match Screening Trial | II | Adv/Met UC, relapsed after standard therapy | P13K, PTEN, AKT, mTOR, BRAF, NRAS, CCND1 | copanlisib or capivasertib or ipatasertib or sapanisertib or trametinib or binimetinib or dabrafenib or palbociclib | 6452 | Recruiting | 02465060 * |
| SEASTAR | Ib/II | Adv/Met UC progressed on 1 previous therapy | DDR, VEGF, FGFRs, PDGFRs | rucaparib + lucitanib rucaparib + sacluzumab govitacen | 329 | Active, not recruiting | 03992131 |

* Trial with additional treatment arms not mentioned in the table. Abbreviations: Adv, Advanced; Met, Metastatic; TSC, Tuberous Sclerosis Complex; HRR, Homologous Recombination Repair; lof, loss of function; GA, Genetic Alteration; Pts, Patients; DDR, DNA Damage Repair; RTKs, Receptor Tyrosine Kinases; PD1/L1, Programmed Death 1/Programmed Death Ligand 1 Inhibitor; ATM, PDGR, Platelet-derived Growth Factor Receptors.

Another potential therapeutic strategy is to target ErbB2 with antibody–drug conjugates (ADCs). ADCs combine a selective monoclonal antibody with a potent cytotoxic...
agent. The ADC, trastuzumab deruxtecan, is being combined with nivolumab in a phase Ib, two-part open-label study in patients with advanced/metastatic urothelial carcinoma who have progressed on prior platinum chemotherapy and have tumor HER2 protein expression based on immunohistochemistry [81]. Of the 30 patients with high expression 2+ or 3+ of Her2, the overall response rate was 36.7%. Activity appeared higher in those with 3+ expression but was also observed in a small group of patients with 1+ expression. Toxicities were consistent with prior reports, and interstitial lung disease/pneumonitis occurred in 23.5% of patients, with one event leading to death. RC48-ADC is another ADC targeting ErbB2, which is being evaluated in combination with toripalimab, an anti-PD-1 antibody, in a phase Ib/II study of patients with advanced/metastatic UC who are cisplatin-ineligible or have progressed on one line of standard chemotherapy [82]. While ErbB2 status was assessed with immunohistochemistry, expression was not required for enrollment. Preliminary results of 32 patients reported an overall response rate of 75%. Of note, 56% of patients enrolled had upper tract UC. Further evaluation of RC48-ADC appears warranted. All in all, early phase clinical trials of ADCs directed at ErbB2 have had promising results but will require validation. Additional trials of RC48-ADC, trastuzumab deruxtecan, and ado-trastuzumab are ongoing (Table 2).

4. PI3K/Akt/mTOR Pathway

The PI3K/Akt/mTOR pathway is an intracellular pathway involved in the regulation of cell cycle progression, cellular growth, angiogenesis, and apoptosis [83,84]. Phosphoinositide-3-kinase (PI3K) is activated by means of a variety of growth factors binding their receptors, including the FGFR and ErbB families of receptors [85,86]. Activated PI3K promotes activation of Akt1 via PIP3 [87]. Activated Akt1 inhibits the tuberous sclerosis complex (TSC) of TSC1 and TSC2. When activated, TSC inhibits Rheb. When Rheb is no longer inhibited by TSC, Rheb is then able to activate mTOR. Activated mTOR proceeds to promote cell cycle progression and cellular growth through interaction with multiple effectors [84]. Another relevant regulator of the PI3k/Akt/mTOR pathway is PTEN. PTEN prevents activation of Akt1 by dephosphorylation of PIP3 [88]. In addition, PTEN regulates cell motility and chemotaxis [89]. There are several other regulators of this key pathway that are beyond the scope of this review.

Genetic alterations in the PI3K/Akt/mTOR pathway are common in urothelial carcinoma. PI3KCA, the catalytic subunit of PI3K, has been noted to be altered in 20–26% of advanced urothelial carcinomas [31,38]. Different activating mutations of PIK3CA vary in their degree of signaling activation and ligand independence [90]. Certain hotspot point mutations in UC, including E545G, are noted to have the highest effects. Akt genetic alterations have been noted in 6% of advanced urothelial carcinomas [38]. The Cancer Genome Atlas Network (TCGA) noted AKT mRNA overexpression in 10% of cases [31]. In addition to its role in the PI3K/Akt/mTOR pathway, increased Akt activity has been shown to reduce apoptosis via resistance to pro-apoptotic ligands [91]. Inactivating mutations or deletions of TSC1 or TSC2 were noted in 6–11% of cases [31,38,92]. The tumor suppressor PTEN was inactivated or deleted in 3–13% of cases [31,38]. Loss of PTEN is also associated with inactivation or deletion of p53 and has been associated with worse patient outcomes and more aggressive tumor features [93–95]. Taken together, genetic alterations within the PI3K/Akt/mTOR pathway have been noted in 42% of cases [31]. PI3K inhibition has been shown to have immunomodulatory effects on immune cells including CD8 and dendritic cells [96]. This provided the rationale for the combination of pan-PI3K inhibition and immune checkpoint inhibition, which exhibited significant antitumor effects in advanced UC with or without activated PI3K pathway by creating an immunostimulatory tumor milieu. Considering the frequency of alterations to the pathway in MIBC, various components of the pathway have understandably been the focus of several targeted therapies.

Despite their biological rationale, inhibitors of the PI3K/Akt/mTOR pathway have not had promising results in clinical trials to date. The PI3K/Akt/mTOR pathway has significant cross-talk with the Ras-ERK pathway [97,98]. There is also some redundancy
in the activation of downstream effectors between the two pathways [98–100]. Due to the inter-pathway regulation, inhibition of the PI3k/Akt/mTOR can result in increased activity of the MAPK pathway and thus serve as a cellular escape mechanism [101]. In addition, inhibition of the PI3k/Akt/mTOR pathway has been shown to lead to increased expression and phosphorylation of multiple receptor tyrosine kinases [102]. This increased expression may further reduce the effectiveness of inhibition of the PI3k/Akt/mTOR pathway.

4.1. PI3K Inhibition

Buparlisib (BKM120) is an orally bioavailable class I PI3K inhibitor which inhibits both wild-type and mutated PI3K [103]. Buparlisib was evaluated in a single-arm, open-label phase II study in patients with locally advanced or metastatic, platinum-refractory UC [104]. The primary endpoint was two-month progression-free survival (PFS). The initial cohort of 16 patients did not select for genetic alterations in the PI3K/Akt/mTOR pathway. The two-month PFS was 54%. In a subsequent genetically selected cohort, patients were selected for PIK3CA, Akt1, or TSC1 mutations. There were only four patients in the genetically selected cohort before study termination by the sponsor. None of the four patients were progression-free at 8 weeks. There were significant adverse events requiring dose reduction in 38% of the cases and causing two patients to withdraw early.

4.2. AKT

MK-2206, an AKT inhibitor, has been primarily studied in breast cancer in phase I and II trials without promising results [105]. Pre-clinical studies have shown MK-2206 potentiates the activity of cisplatin in urothelial carcinoma; however, this has not been further evaluated in clinical trials [106].

4.3. mTOR

Rapamycin, also called sirolimus, was the first mTOR inhibitor discovered [107]. It has been shown to inhibit the mTORC1 complex, which is one of the downstream effector complexes of mTOR involved in the regulation of translation and cell growth [107,108]. There are now additional mTOR inhibitors including temsirolimus and everolimus [107].

mTOR inhibitors have an established role in the treatment of other cancers such as advanced kidney cancer and pancreatic neuroendocrine tumors [109,110]. Pre-clinical studies of mTOR inhibitors in urothelial cancer have demonstrated dose-dependent inhibition of proliferation in UC cell lines [111]. However, clinical trials of mTOR inhibitors in patients with UC have generally performed poorly.

Everolimus was evaluated in a single-arm, phase II trial in patients with metastatic UC who had progressed on at least one cytotoxic agent [112]. The study enrolled 45 patients and did not meet its primary endpoint. The progression-free survival at two months was 51%. However, there were two patients with partial responses. One patient had a durable complete response of over two years. Subsequent genetic analysis of that patient’s tumor genome identified a TSC1-inactivating mutation as well as a mutation in neurofibromatosis type 2 (NF2) [113].

Everolimus was evaluated in another open-label, single-arm phase II trial in patients with advanced or metastatic transitional cell carcinoma who had progressed on platinum-based chemotherapy [114]. The disease control rate at two months was 27%. This trial identified that PTEN loss was observed only in patients with progressive disease. PTEN expression was detected in all 6 patients with controlled disease and in 6 of 14 patients (43%) with noncontrolled disease. In a subsequent study analyzing archival tissue from the participants, it was found that the PTEN-deficient cells had increased Akt activation upon treatment with an mTOR inhibitor [115]. The authors suggest that the increased Akt activation upon exposure to mTOR inhibition in PTEN deficient tumors was a possible resistance mechanism to everolimus. In addition to PTEN deficiency, Akt activity may be increased in this setting because everolimus, which selectively blocks a subunit of mTORC1, may lead to increased mTORC2 activation, which is known to activate Akt [116]. Everolimus in
addition to paclitaxel was trialed in a phase II trial of second-line treatment after failure of platinum-based chemotherapy in advanced UC [117]. The overall response rate was only 13%. Unfortunately, an umbrella trial evaluating everolimus and enrolling patients with advanced solid tumors that harbored TSC1/TSC2 or mTOR mutations demonstrated poor outcomes [118]. Partial responses were seen in only 2 patients of 30 patients, and there was no clear association between other genomic alterations and response. Of the two patients with response, one had upper tract urothelial carcinoma with biallelic inactivation of TSC1 and high tumor mutational burden.

Temsirolimus was evaluated in a phase II trial of patients with recurrent or metastatic UC who have received first-line chemotherapy [119]. Of the 45 patients evaluated, 48.9% had non-progression at two months. Four patients were treated for over 30 weeks. Of note, 52.8% had grade 3 or 4 toxicities, and 11 patients stopped treatment due to toxicity. For this reason, recruitment was halted in the trial. Another phase II trial of temsirolimus as second-line therapy in patients with metastatic UC was stopped early due to lack of sufficient benefit [120].

Sapanisertib, unlike the mTOR inhibitors discussed above, inhibits both mTORC1 and mTORC2 complexes [121]. By inhibiting mTORC2 as well, Akt activity is not subsequently upregulated [122]. A phase II trial of sapanisertib in locally advanced or metastatic UC with TSC1 or TSC2 mutations who have developed disease progression after platinum-based chemotherapy was terminated early for futility as well as for a high prevalence of adverse events (hyperglycemia, acute kidney injury, and elevated liver enzymes [123].

Dactolisib, (BEZ235) a PI3K and mTORC1/2 inhibitor, was evaluated in a phase II trial in UC [124]. Dactolisib demonstrated modest clinical activity, and the progression-free survival at 16 weeks was 10%. There was also considerable toxicity. The combination of durvalumab and an investigational mTORC1/2 inhibitor did not appear to improve efficacy following platinum-based chemotherapy in the BISCAY trial [64].

4.4. Possible Future Therapeutic Strategies Targeting the PI3K/Akt/mTOR Pathway

In light of the identified mechanisms of resistance to PI3K/Akt/mTOR inhibition, there are a few potential pathways forward. One option includes combining inhibition of the PI3K/Akt/mTOR pathway and the MAPK pathway. Inhibition of the two pathways simultaneously has been evaluated in various cancers and has been complicated by significant toxicities in most clinical trials to date [125]. However, the combination was tolerated in a more recent phase I trial with BRAF inhibition/PI3K inhibition in patients with melanoma or gastrointestinal stromal tumors [126]. There may still be a possibility of finding a tolerable combination of PI3K/Akt/mTOR inhibitor and MAPK pathway inhibitor in urothelial carcinoma.

The noted upregulation of RTKs with inhibition of PI3K/Akt/mTOR pathway raises the possibility that combining inhibition of both pathways may be more effective. Everolimus and pazopanib, a vascular endothelial growth factor (VEGF)-receptor inhibitor, was evaluated in patients with locally advanced or metastatic UC as an expansion cohort from a phase I trial of patients with advanced cancer [114]. The overall response rate was 21%. Mutations in TSC1/2 or mTOR were noted in a subset of the patients who derived a clinical benefit. Four of five patients with clinical benefit had mutations in TSC1/TSC2 or mTOR, and a fifth patient had a FGFR3-TACC3 fusion. Combined PIK3CA and FGFR inhibition was evaluated in patients with various PIK3CA-mutated solid tumors in a phase IB dose-escalation and expansion study [127]. This study noted grade 3 or 4 adverse events in 60% of patients. Interestingly, dose-limiting toxicities were only noted in 10% of cases. While the study was not powered for efficacy, the partial response rate was only 9.7%. There were no clear genetic associations with partial response after performing next-generation sequencing.

Despite the modest results of these trials, further evaluation of combination RTK and PI3K/Akt/mTOR pathway inhibition is warranted. In the trials above, there were occasionally patients who experienced exceptional responses from PI3K/Akt/mTOR path-
way inhibition [113]. These occurrences suggest that there may be a particular subset of patients who will receive substantial benefit from inhibition of this pathway. The challenge remains in identifying who those exceptional responders will be. Attempts have been made with next-generation sequencing to identify mechanistic explanations for responders and non-responders, with mixed results [113,127]. More sophisticated molecular matching in an individual’s tumor’s genetic makeup may further improve outcomes [127,128].

5. MAPK Pathway

The mitogen-activated protein kinase (MAPK) signaling pathway is involved in cellular proliferation, growth, and survival [129]. In general, the activation of the MAPK pathway begins with growth factors binding their associated receptors, i.e., epithelial growth factor binding EGFR [130]. The tyrosine kinase receptor binding leads to activation of Ras GTPase (Ras), which is located intracellularly [131]. An activation cascade ensues, with RAS subsequently activating RAF, which then activates mitogen-activated protein kinase (MEK), which then activates MAPK [131,132]. Of note, there are 3 MAPks, each with multiple isoforms (ERks, JNks, and p38-MAPks). While there is significant overlap in their role/function, the ERks are typically activated in response to growth stimuli, while JNks and p38-MAPks are activated in response to cellular stress and can have both anti- and pro-apoptotic effects [133]. By way of multiple downstream effectors, including c-Myc and NF-kb, MAPK is involved in the regulation of translation, differentiation, and the cell cycle [131,132]. There is frequent and complex cross-talk with several other intracellular pathways including the PI3K/Akt/mTOR pathway [101]. Genetic alterations in the MAPK pathway have been implicated in a wide array of malignancies including urothelial carcinoma [131]. In urothelial carcinoma, genetic alterations in RAS have been implicated in 2–5% of cases [31,134]. BRAF mutations have been noted in 2% of cases [134].

MAPK Pathway Inhibitors

While there is a lower frequency of MAPK pathway genetic alterations in urothelial carcinoma than many of the potential therapeutic pathways already discussed, its interaction with more frequently mutated pathways and receptors lends it clinical relevance. Therapies directed at inhibition of the MAPK pathway have had mixed results. Tipifarnib is a farnesyltransferase inhibitor that has been shown to inhibit RAS function [135]. Tipifarnib was evaluated in a phase II clinical trial in patients with metastatic urothelial carcinomas with HRAS mutations [136]. Of the 21 patients evaluated, 19% had progression-free survival at 6 months, suggesting poor activity.

Sorafenib is an inhibitor with activity against multiple kinases including RAF [137]. Sorafenib as a single agent was found to have minimal activity in a phase II trial of patients with advanced urothelial carcinoma [138]. A phase I clinical trial of the combination of sorafenib and vinflunine was notable for an overall response rate of 41% in patients with post-platinum metastatic UC [139]. A phase II trial assessed sorafenib in combination with gemcitabine and carboplatin as first-line therapy in metastatic or unresectable UC [140]. While this study reports a median progression-free survival of 9.5 months, there were significant toxicities with the regimen leading to 65% of the cohort discontinuing treatment [140]. Further evaluation with phase III studies of sorafenib in combination with vinflunine or gemcitabine/carboplatin is warranted. In addition, patient selection based on genetic alterations in RAF may further augment results. The inhibition of the MAPK pathway may have a clinically relevant role, especially in combination with chemotherapy or when combined with additional targeted therapy.

6. Chromatin Remodeling

One of the striking findings in the Cancer Genome Atlas’ analysis of muscle-invasive bladder cancer was the frequency of genetic alterations in chromatin regulatory genes [31]. Urothelial carcinoma had some of the highest rates of alterations in chromatin regulatory genes of any cancer type. Dysregulation of chromatin remodeling was present in 89%
of the samples. Some of the most commonly affected genes were MLL2 (27%), ARID1 (25%), KDM6A (24%), and EP300 (15%). The regulation of chromatin is an attractive therapeutic target because of its relevance to cellular plasticity, differentiation, DNA repair, transcription regulation, and many other nuclear functions [141]. However the specific pathogenetic implications of these mutations have not yet been sufficiently studied.

Therapies Directed at Chromatin Remodeling

The relative frequency of these mutations does increase the potential yield of targeted therapies. Some hypothesize that genetic alterations in chromatin regulation may create an opportunity to exploit synthetic lethality by the targeted inhibition of additional chromatin regulators [141]. Synthetic lethality occurs when the simultaneous disruption of two genes/proteins leads to cellular death only when used in combination [142]. This principle can be exploited in cancer cells that already carry genetic alterations by addition of a synthetically lethal inhibitor. For instance, synthetic lethality has been demonstrated in ARID1A mutated cancers by inhibition of EZH2 methyltransferase in vivo [143]. Therapies such as histone deacetylase inhibitors (HDACi) have been suggested and are currently being evaluated [144]. The HDACi, vorinostat, was previously evaluated in urothelial carcinoma as a single agent and was found to be limited by toxicities [145]. Vorinostat is now being evaluated in conjunction with pembrolizumab in patients with advanced UC (NCT02619253). Mocetinostat was evaluated as a single agent in a phase II trial of patients with advanced/metastatic urothelial carcinoma and a genetic alteration in genes involved in chromatin remodeling, CREBBP, or EP300 [146]. Significant toxicities were noted leading to treatment interruptions and dose reductions. The study was terminated early due to lack of efficacy. The HDACi, belinostat, is currently being evaluated in combination with tremelimumab and durvalumab in patients with ARID1A mutations and unresectable, metastatic, or locally advanced UC (NCT05154994). Tazemoostat, an EZH2 inhibitor, is being evaluated in combination with pembrolizumab in a phase I/II trial of patients with locally advanced/metastatic urothelial carcinoma who have progressed on platinum chemotherapy or are platinum-ineligible (NCT03854474). Finally, as DNA repair can be inhibited by alterations in chromatin regulatory genes, a possible therapeutic strategy is to inhibit DNA repair with agents such as PARP inhibitors [141,147]. The evaluation of PARP inhibitors in MIBC is discussed later. All in all, chromatin remodeling is a promising therapeutic target in the management of MIBC.

7. Cell Cycle Regulation

The regulation of the cell cycle is another relevant target in bladder cancer. CDKN2A/B, the gene for p14 and p16, which inhibit the cyclin-dependent kinases, Cdk4 and Cdk6, is altered in 5–23% of cases of MIBC [31,38]. CCND1 (10–14% genetic alterations) and CCND3 (4–11% genetic alterations) encode for cyclins that promote cell cycle progression via interactions with Cdk4 and Cdk6. CDKN1A, a potent cyclin-dependent kinase inhibitor, is genetically altered in 14% of cases. The tumor suppressor RB1 is genetically altered in 13–17% of cases, while Tp53 is genetically altered in 49–54% of cases. MDM2, an important regulator of Tp53, is genetically altered in 9–11% of cases. All in all, cell cycle regulation is genetically altered in up to 93% of cases of muscle-invasive bladder cancer [31].

CDK Inhibitors

CDK4/6 inhibition has been a therapeutic target in many solid cancers including urothelial carcinoma. Palbociclib, a CDK4/6 inhibitor was evaluated in a phase II trial of patients with metastatic, platinum-refractory urothelial carcinoma with loss of p16 and intact Rb. Unfortunately, Palbociclib was not effective; only 17% of patients achieved progression-free survival at 4 months [148]. In an analysis of mechanisms of resistance to CDK 4/6 inhibition, Tong et al. demonstrated alterations in DNA repair pathways are likely involved [149]. They have subsequently demonstrated the effectiveness of the combination of CDK 4/6 inhibition with a PARP inhibitor in pre-clinical studies [150]. This warrants
further clinical study. The combination of abemaciclib, a CDK4/6 inhibitor, and CRISPR knockout of CDKN2A is being evaluated in a phase I trial in the neoadjuvant setting in platinum-ineligible patients (NCT03837821) [151]. Trilaciclib, another CDK 4/6 inhibitor, is being evaluated in patients with advanced/metastatic UC receiving chemotherapy followed by avelumab, which is predicated to improve outcomes by protection from myelo-suppression of chemotherapy as well as enhance the immune tumor microenvironment by inducing a transient G1 cell cycle arrest of hematopoietic cells (NCT04887831).

8. DNA Damage Repair

Genetic alterations in DNA damage response (DDR) genes are also prevalent in bladder cancer. ERCC1 and ERCC2, which are components of the nucleotide excision repair pathway, are implicated [31,152]. Additional DDR genetic alterations include BRCA1/2 (6% and 14%, respectively), ATM (12%), RB1 (13–17%), and FANCC (2%) [31]. In general, DDR genetic alterations have been associated with improved responses to chemotherapy and immune checkpoint inhibitors, as well as improved responses to immune checkpoint inhibitors [4,153–156].

Targeting Alterations in DNA Damage Repair

Targeted therapy towards urothelial carcinoma with DDR genetic alterations includes the usage of poly ADP-ribose polymerase (PARP) inhibitors. PARP enzymes are involved in repairing single-strand and double-strand DNA breaks. PARP inhibitors take advantage of the concept of synthetic lethality in tumor cells that have deficiencies in DNA repair [157].

Relevant PARP inhibitors include rucaparib, olaparib, niraparib, and talazoparib. Rucaparib was evaluated in patients with previously treated advanced or metastatic urothelial carcinoma, regardless of tumor homologous recombination deficiency (HRD) status [158]. Of the 97 patients enrolled, there were no confirmed responses. The study was terminated for lack of efficacy. However, patient selection for HRD status may have been suboptimal based on genome-wide loss of heterozygosity (LOH).

Olaparib is also being evaluated in combination with the immune checkpoint inhibitor durvalumab. A phase II trial in the neoadjuvant setting demonstrated tolerability of the regimen as well as efficacy, with a 50% pathologic complete response rate at the time of cystectomy [159]. The combination was evaluated in patients with advanced disease who had progressed on platinum-based chemotherapy in a multi-arm, multi-agent trial (BISCAY) [64]. The patients with and without DNA homologous recombination repair deficiencies were evaluated in separate treatment arms. The combination did not meet the efficacy criteria for continuation. Olaparib was also evaluated in combination with durvalumab in a phase II randomized trial in patients with metastatic UC who were platinum-chemotherapy-ineligible and had not previously received chemotherapy for stage IV disease [160]. A total of 154 patients were randomized to receive durvalumab with placebo or durvalumab with olaparib. The median PFS was not significantly different for durvalumab and placebo vs. durvalumab and olaparib. However, in a pre-specified subset of patients with homologous recombination repair (HRR) mutations, the progression-free survival was significantly improved in the group receiving olaparib and durvalumab (5.6 months vs. 1.8 months). Another randomized phase II trial demonstrated a trend for improved PFS with switch maintenance rucaparib in those with stable or responding disease on platinum-based chemotherapy [161]. The observed benefit in the subset of patients with HRR mutations confirms the importance of using biomarkers to select patients in subsequent evaluations of PARP inhibitors.

Olaparib is also being evaluated in a phase II study of patients with advanced or metastatic UC who have progressed on chemotherapy or immune checkpoint inhibitors and have genetic alterations in several DDRs including BRCA1, BRCA2, ATM, MSH2, PALB2, BRIP1, and many others (NCT03375507). PARP inhibitors in this setting are also included in two additional ongoing umbrella studies (NCT03682289, NCT03869190, NCT03992131).
PARP inhibition has also been evaluated as maintenance therapy in the metastatic setting. Niraparib was evaluated as maintenance therapy in metastatic UC after patients achieved an objective response (OR) or stable disease (SD) after receipt of first-line platinum-based chemotherapy [162]. Of the 58 patients enrolled, 39 were randomized to niraparib, and 19 were randomized to placebo. There was no difference between arms in progression-free survival. This study did not require DDR genetic alterations to be present for enrollment. While there was no improvement in PFS in the 21 patients with HRR genetic abnormalities, it is possible that a larger sample size of patients with DDR genetic alterations would be necessary to observe an effect. Rucaparib was evaluated in a phase II trial as maintenance therapy following platinum-based chemotherapy in patients with metastatic disease that exhibits DNA repair deficiency [161]. There was an improvement in PFS in patients receiving rucaparib vs. placebo (Median PFS 35.3 weeks vs. 15.1 weeks, respectively; HR 0.53, 80% CI 0.3–0.92). These results suggest that PARP inhibition may be more effective in patients whose disease is responsive to platinum-based therapies. Additional clinical trials are ongoing that evaluate PARP inhibitors as maintenance therapy in the metastatic setting in combination with an immune checkpoint inhibitor or in combination with a receptor tyrosine kinase inhibitor (Table 2).

To this date, PARP inhibitors have not shown promising results in the treatment of urothelial carcinoma. It is possible that patient selection could be optimized to improve the results. Further work is needed to select patients with the highest chance of benefiting from PARP inhibitors. In addition, the ongoing studies assessing PARP inhibitors in novel clinical settings, such as maintenance therapy, may prove to be efficacious.

9. Emerging Therapeutic Targets and Future Directions

In addition to the genetic alterations in the pathways discussed above, there are additional emerging therapeutic targets. Multi-kinase inhibitors such as cabozantinib (inhibitor of VEGFR2, c-MET, RET) are being evaluated in multiple settings of UC [163,164]. Cabozantinib was evaluated in a phase II trial as a single agent in patients with metastatic platinum-refractory UC [165]. The objective response rate was 19%. There are several trials ongoing with cabozantinib in addition to PD1/L1 inhibitors in the advanced and metastatic setting (Table 2). Pembrolizumab with lenvatinib, a multikinase inhibitor, was evaluated in a phase III, randomized, double-blinded trial of patients with advanced/metastatic UC ineligible to receive cisplatin-expressing PD-L1 or ineligible to receive platinum-based chemotherapy regardless of PD-L1 status [166]. Among these patients, 218 were randomized to pembrolizumab and placebo, while 223 were randomized to pembrolizumab and lenvatinib. There was no difference in progression-free survival or overall survival. There were more grade 3–5 adverse events in the group receiving lenvatinib (50% vs. 27.9%). Of note, the results were possibly compromised by a high proportion of poor-performance-status patients and by not incorporating biomarkers for FGFR GAs or other RTK GAs relevant to lenvatinib. Of note, lenvatinib has been associated with significant cardiotoxicity including QT interval prolongation and cardiotoxicity [167,168]. Among patients with lenvatinib, 7% were noted to develop cardiac dysfunction, with 2% noting grade 3 or greater. In addition to multi-kinase inhibitors, berzosertib, an inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein, was evaluated in addition to chemotherapy in patients with metastatic UC who had not yet received chemotherapy for metastatic disease [169]. Unfortunately, there was no improvement in progression-free survival.

As advances in the understanding of the pathogenic mechanisms involved in cancer continue, there will undoubtedly be novel approaches to target genetic alterations in urothelial carcinoma. Emerging evidence is adding to our understanding of the role that phenotypic plasticity, epigenetic reprogramming, cellular senescence, the tumor microenvironment, and polymorphic microbiomes have in pathogenesis [170,171]. We anticipate attempts to target the recently appreciated pillars of pathogenesis will be forthcoming.

In recent years, there has been a welcomed increase in the availability of advanced and increasingly comprehensive genetic analysis of tumors. In tandem, there is also a growing
appreciation of the genetic complexity of tumors; genetic alterations can be heterogeneously distributed within a tumor, especially in chemotherapy resistant tumors [172]. Refining patient selection in clinical trials is important to improving outcomes of targeted therapies in urothelial carcinoma. At a minimum, we suggest that patients evaluated in clinical trials for targeted therapies should have tumors with relevant genetic alterations. However, the presence of a genetic alteration alone does not suggest pathogenic relevance. The development of strategies to identify key pathogenic mutations more precisely in an individual tumor are needed to improve outcomes with targeted therapy.

10. Conclusions

The management of muscle-invasive and advanced bladder cancer has changed dramatically in the past five years. As the genetic alterations key to the pathogenesis of MIBC are identified at an accelerating pace, the potential for breakthroughs accelerates as well. From tyrosine kinase receptors to intracellular pathways to intranuclear processes, targeted therapies are being developed. At this point, targeting FGFR with erdafitinib is the most effective targeted therapy. There remains much to be learned about how erdafitinib can best be employed in the management of MIBC. There are also several other FGFR inhibitors being evaluated in various treatment settings and combination therapies. Meanwhile, targeting the ErbB receptors, PI3K/Akt/mTOR, MAPK, chromatin remodeling, cell cycle regulation, and DNA damage repair pathways have had mixed results. Despite this, there remains reason for optimism that with advanced molecular characterization of tumors, patient selection can continue to improve so that additional targeted therapies will be identified to further improve patient outcomes.

Author Contributions: Conceptualization, J.T. and G.S.; writing—original draft preparation, J.T.; writing—review and editing, G.S.; visualization, J.T.; supervision, G.S. All authors have read and agreed to the published version of the manuscript.

Funding: This review received no external funding.

Acknowledgments: Figure 1 was created with biorender.com (accessed on 22 February 2022).

Conflicts of Interest: Jonathan Thomas has no conflict of interest. Disclosures for Guru Sonpavde: Advisory Board: BMS: Genentech, EMD Serono, Merck, Sanofi, Seattle Genetics/Astellas, Astrazeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, G1 Therapeutics, Eli Lilly/Loxo Oncology, Infinity Pharmaceuticals; Research Support: Sanofi, Astrazeneca, Gilead, QED, Lucence, Predicine, BMS; Steering committee of studies: BMS, Bavarian Nordic, Seattle Genetics, QED, G1 Therapeutics (all unpaid), and Astrazeneca, EMD Serono, Debiopharm (paid); Data safety monitoring committee: Mereo; Employment: Spouse employed by Myriad; Travel costs: BMS, Astrazeneca; Writing/Editor fees: Uptodate, Editor of Elsevier Practice Update Bladder Cancer Center of Excellence; Speaking fees: Physicians Education Resource (PER), Onclive, Research to Practice, Medscape, Cancer Network, Masters Lecture Series (MLS). The funders had no role in the design of the study or in the collection, analyses, or interpretation of data/results.

References
1. Lenis, A.T.; Lec, P.M.; Chamie, K.; Mshs, M. Bladder Cancer. JAMA 2020, 324, 1980. [CrossRef]
2. The Global Cancer Observatory. Bladder. Available online: https://gco.iarc.fr/today/data/factsheets/cancers/30-Bladder-factsheet.pdf (accessed on 6 January 2022).
3. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 2022, 72, 7–33. [CrossRef]
4. von der Maase, H.; Sengelov, L.; Roberts, J.T.; Ricci, S.; Dogliotti, L.; Oliver, T.; Moore, M.J.; Zimmermann, A.; Arning, M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 2005, 23, 4602–4608. [CrossRef]
5. De Santis, M.; Bellmunt, J.; Mead, G.; Kerst, J.M.; Leahy, M.; Maroto, P.; Gil, T.; Marreau, S.; Dauggaard, G.; Skoneczna, I.; et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J. Clin. Oncol. 2012, 30, 191–199. [CrossRef]
6. Bellmunt, J.; De Wit, R.; Vaughan, D.J.; Fradet, Y.; Lee, J.-L.; Fong, L.; Vogelzang, N.J.; Climent, M.A.; Petrylak, D.P.; Choueiri, T.K.; et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. *N. Engl. J. Med.* 2017, 376, 1015–1026. [CrossRef]  

7. Massard, C.; Gordon, M.S.; Sharma, S.; Rafii, S.; Wainberg, Z.A.; Luke, J.; Curiel, T.J.; Colon-Otero, G.; Hamid, O.; Sanborn, R.E.; et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer. *J. Clin. Oncol.* 2016, 34, 3119–3125. [CrossRef]  

8. Patel, M.R.; Ellerton, J.; Infante, J.R.; Agrawal, M.; Gordon, M.; Aljumaily, R.; Britten, C.D.; Dixit, L.; Lee, K.W.; Taylor, M.; et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): Pooled results from two expansion cohorts of an open-label, phase 1 trial. *Lancet Oncol.* 2018, 19, 51–64. [CrossRef]  

9. Rosenberg, J.E.; Hoffman-Censits, J.; Powles, T.; Van Der Heijden, M.S.; Balar, A.V.; Necchi, A.; Dawson, N.; O’Donnell, P.H.; Balmanoukian, A.; Lorigi, Y.; et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. *Lancet* 2016, 387, 1909–1920. [CrossRef]  

10. Powles, T.; Park, S.H.; Voog, E.; Caserta, C.; Valderrama, B.P.; Gurney, H.; Kalofonos, H.; Ullén, A.; et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. *N. Engl. J. Med.* 2020, 383, 1218–1230. [CrossRef]  

11. National Comprehensive Cancer Network. Bladder Cancer. Available online: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf (accessed on 6 January 2022).  

12. Tagawa, S.T.; Balar, A.V.; Petrylak, D.P.; Kalebasty, A.R.; Lorigi, Y.; Flechon, A.; Jain, R.K.; Agarwal, N.; Bupathi, M.; Barthelemy, P.; et al. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. *J. Clin. Oncol.* 2021, 39, 2474–2485. [CrossRef]  

13. Powles, T.; Rosenberg, J.E.; Sonpavde, G.P.; Lorigi, Y.; Durán, I.; Lee, J.-L.; Matsubara, N.; Vulsteke, C.; Castellano, D.; Wu, C.; et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. *N. Engl. J. Med.* 2021, 384, 1125–1135. [CrossRef]  

14. Beenken, A.; Mohammad, M. The FGFR family: Biology, pathophysiology and therapy. *Nat. Rev. Drug Discov.* 2009, 8, 235–253. [CrossRef]  

15. di Martino, E.; Tomlinson, D.C.; Knowles, M.A. A Decade of FGFR Receptor Research in Bladder Cancer: Past, Present, and Future Challenges. *Adv. Urol.* 2012, 2012, 429213. [CrossRef]  

16. Robertson, A.G.; Kim, J.; Al-Ahmadie, H.; Bellmunt, J.; Guo, G.; Cherniack, A.D.; Hinoue, T.; Laird, P.W.; Hoadley, K.A.; Lahaye, J.-B.; Abbou, C.C.; et al. Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors. *Am. J. Pathol.* 2001, 158, 1955–1999. [CrossRef]  

17. Perera, T.P.S.; Jovcheva, E.; Mevellec, L.; Viallard, J.; De Lange, D.; Verhulst, T.; Paulussen, C.; Van De Ven, K.; King, P.; Freyne, E.; et al. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdfatinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor. *Mol. Cancer* 2017, 16, 1010–1020. [CrossRef]  

18. Beenken, A.; Mohammad, M. The FGFR family: Biology, pathophysiology and therapy. *Nat. Rev. Drug Discov.* 2009, 8, 235–253. [CrossRef]  

19. Mohammad, M.; Dikic, I.; Sorokin, A.; Burgess, W.H.; Jaye, M.; Schlessinger, J. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. *Mol. Cell Biol.* 1996, 16, 977–989. [CrossRef]  

20. Ornitz, D.M.; Yacono, A.; Flanagan, J.G.; Svanhn, C.M.; Levi, E.; Leder, P. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. *Mol. Cell Biol.* 1992, 12, 240–247. [CrossRef]  

21. Schlessinger, J.; Plotnikov, A.N.; Ibrahim, O.A.; Eliseenkova, A.V.; Yeh, B.K.; Yazono, A.; Linhardt, R.J.; Mohammad, M. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. *Mol. Cell* 2000, 6, 743–750. [CrossRef]  

22. Klint, P.; Claesson-Welsh, L. Signal transduction by fibroblast growth factor receptors. *Front. Biosci.* 1999, 4, D165–D177. [CrossRef]  

23. Tomlinson, D.C.; Baldo, O.; Harnden, P.; Knowles, M.A. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. *J. Pathol.* 2007, 213, 91–98. [CrossRef]  

24. Kimura, T.; Suzuki, H.; Ohashi, T.; Asano, K.; Kiyota, H.; Eto, Y. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. *Cancer* 2001, 92, 2555–2561. [CrossRef]  

25. Adar, R.; Monsonego-Ornan, E.; David, P.; Yazono, A. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization. *J. Bone Miner. Res.* 2002, 17, 860–868. [CrossRef]  

26. d’Avis, F.Y.; Robertson, S.C.; Meyer, A.N.; Birdwell, W.M.; Webster, M.K.; Donoghue, D.J. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. *Cell Growth Differ.* 1998, 9, 71–78.  

27. Ravery, V.; Jouanneau, J.; Gil Diez, S.; Abbou, C.C.; Caruelle, J.P.; Barritault, D.; Chopin, D.K. Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma. *Urol. Res.* 1992, 20, 211–214. [CrossRef]
28. Nassar, A.H.; Lundgren, K.; Pomerantz, M.; Van Allen, E.; Harshman, L.; Choudhary, A.D.; Preston, M.A.; Steele, G.S.; Mouw, K.W.; Wei, X.X.; et al. Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. JCO Precis. Oncol. 2018, 2. [CrossRef]

29. Hood, F.E.; Royle, S.J. Pulling it together: the mitotic function of TACC3. Bioarchitecture 2011, 1, 105–109. [CrossRef]

30. Parker, B.C.; Annala, M.J.; Cogdell, D.E.; Granberg, K.J.; Sun, Y.; Ji, P.; Li, X.; Gumin, J.; Zheng, H.; Hu, L.; et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J. Clin. Investig. 2013, 123, 855–865. [CrossRef]

31. Weinstein, J.N.; Akbani, R.; Broom, B.M.; Wang, W.; Verhaak, R.G.W.; McConkey, D.; Lerner, S.; Morgan, M.; Creighton, C.J.; Smith, C.; et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507, 315–322. [CrossRef]

32. Helston, T.; Elkin, S.; Arthur, E.; Tomson, B.N.; Carter, J.; Kurzrock, R. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin. Cancer Res. 2016, 22, 259–267. [CrossRef]

33. Stranks, N.; Cerami, E.; Schalin, S.; Kim, J.L.; Lengauer, C. The landscape of kinase fusions in cancer. Nat. Commun. 2014, 5, 4846. [CrossRef]

34. Nelson, K.N.; Meyer, A.N.; Siari, A.; Campos, A.R.; Motamedchaboki, K.; Donoghue, D.J. Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation. Mol. Cancer Res. 2016, 14, 458–469. [CrossRef]

35. Costa, R.; Carneiro, B.A.; Taxter, T.; Tavora, F.A.; Kalyan, A.; Pai, S.A.; Chae, Y.K.; Giles, F.J. FGFR3-TACC3 fusion in solid tumors: Mini review. Oncotarget 2016, 7, 55924–55938. [CrossRef]

36. Sarkar, S.; Ryan, E.L.; Royle, S.J. FGFR3-TACC3 cancer gene fusions cause mitotic defects by removal of endogenous TACC3 from the mitotic spindle. Open Biol. 2017, 7. [CrossRef]

37. Singh, D.; Chan, J.M.; Zoppoli, P.; Niola, F.; Sullivan, R.; Castano, A.; Liu, E.M.; Reichel, J.; Porprati, P.; Pellegratta, S.; et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012, 337, 1231–1235. [CrossRef]

38. Ross, J.S.; Wang, K.; Al-Rohil, R.N.; Naezer, T.; Sheehan, C.E.; Otto, G.A.; He, J.; Palmer, G.; Ylenksis, R.; Lipson, D.; et al. Advanced urothelial carcinoma: Next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod. Pathol. 2014, 27, 271–280. [CrossRef]

39. Tomlinson, D.C.; Baxter, E.W.; Loadman, P.M.; Hull, M.A.; Knowles, M.A. FGFR1-Induced Epithelial to Mesenchymal Transition through MAPK/PLCγ/Cox-2-Activated Mechanisms. PLoS ONE 2012, 7, e38972. [CrossRef]

40. Tomlinson, D.C.; Lamont, F.R.; Shnyder, S.D.; Knowles, M.A. Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer. Cancer Res. 2009, 69, 4613–4620. [CrossRef]

41. Katoh, M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat. Rev. Clin. Oncol. 2019, 16, 105–122. [CrossRef] [PubMed]

42. Chell, V.; Balmanno, K.; Little, A.S.; Wilson, M.; Andrews, S.; Blockley, L.; Hampson, M.; Gavine, P.R.; Cook, S.J. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR2 as a mechanism of acquired resistance. Oncogene 2013, 32, 3059–3070. [CrossRef]

43. Cowell, J.K.; Qin, H.; Hu, T.; Wu, Q.; Bhole, A.; Ren, M. Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemias/lymphomas. Int. J. Cancer 2017, 141, 1822–1829. [CrossRef] [PubMed]

44. Goyal, L.; Saha, S.K.; Liu, L.Y.; Siravegna, G.; Leshchiner, I.; Ahronian, L.G.; Lerner, J.K.; Vu, P.; Deshpande, V.; Kambadakone, A.; et al. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov. 2017, 7, 252–263. [CrossRef] [PubMed]

45. Meric-Bernstam, F.; Bahleda, R.; Hierro, C.; Sanson, M.; Bridgewater, J.; Arkenau, H.T.; Tran, B.; Kelley, R.K.; Park, J.O.; Javle, M.; et al. Futibatimib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGFR/FGFR2 Aberrations: A Phase I Dose-Expansion Study. Cancer Discov. 2022, 12, 402–415. [CrossRef] [PubMed]

46. Nakanishi, Y.; Akiyama, N.; Tsukaguchi, T.; Fujii, T.; Sakata, K.; Sase, H.; Iseobe, T.; Morikami, K.; Shinoh, H.; Mio, T.; et al. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol. Cancer 2014, 13, 2547–2558. [CrossRef] [PubMed]

47. Roskoski, R., Jr. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharm. Res. 2020, 151, 10467. [CrossRef]

48. Lamont, D.; Tomlinson, D.C.; Cooper, P.A.; Shnyder, S.D.; Chester, J.D.; Knowles, M.A. Small molecule FGFR inhibitor block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br. J. Cancer 2011, 104, 75–82. [CrossRef]

49. Rolfo, C.; Raez, L.E.; Bronte, G.; Santos, E.S.; Papadimitriou, K.; Buffoni, L.; Van Meerbeeck, J.P.; Russo, A. BIBF 1120/nintedanib: A new triple angiotakinase inhibitor-directed therapy in patients with non-small cell lung cancer. Expert Opin. Investig. Drugs 2013, 22, 1081–1088. [CrossRef]

50. Taylor, M.H.; Lee, C.H.; Makker, V.; Rasco, D.; Dutcus, C.E.; Wu, J.; Stepian, D.E.; Shumaker, R.C.; Motzer, R.J. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. J. Clin. Oncol. 2020, 38, 1154–1163. [CrossRef]

51. Loriot, Y.; Necchi, A.; Park, S.H.; Garcia-Donas, J.; Huddart, R.; Burgess, E.; Fleming, M.; Rezazadeh, A.; Mellado, B.; Varlamov, S.; et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N. Engl. J. Med. 2019, 381, 338–348. [CrossRef]
52. Siefker-Radtke, A.O.; Necchi, A.; Park, S.H.; Garcia-Donas, J.; Huddart, R.A.; Burgess, E.F.; Fleming, M.T.; Rezazadeh Kalebasty, A.; Mellado, B.; Varlamov, S.; et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: Long-term follow-up of a phase 2 study. *Lancet Oncol.* 2022, 23, 248–258. [CrossRef]

53. Loriot, Y.; Necchi, A.; Olayioye, M.A.; Neve, R.M.; Lane, H.A.; Hynes, N.E. The ErbB signaling network: Receptor heterodimerization in development. *N. Engl. J. Med.* 2019, 381, 1593–1595. [CrossRef] [PubMed]

54. Wang, L.; Gong, Y.; Sacci, A.; Szabo, P.M.; Martini, A.; Necchi, A.; Siefker-Radtke, A.; Pal, S.; Pлимак, E.R.; Sfakianos, J.P.; et al. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. *Eur. Urol.* 2019, 76, 599–603. [CrossRef] [PubMed]

55. Schuler, M.; Cho, B.C.; Sayehli, C.M.; Navarro, A.; Soo, R.A.; Richly, H.; Cassier, P.A.; Tai, D.; Penel, N.; Nogova, L.; et al. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: A phase 1 dose-escalation and dose-expansion study. *Lancet Oncol.* 2019, 20, 1454–1466. [CrossRef]

56. Powles, T.; Chistyakov, V.; Beliakouski, V.; Semenov, A.; Everaert, E.; Baranau, Y.; Moreno, V.; Valderrama, B.P.; Vano, Y.; Del Conte, G.; et al. LBA27 Erdafitinib (ERDA) or ERDA plus cetetimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study. *Ann. Oncol.* 2021, 32, S1303. [CrossRef]

57. Quinn, D.I.; Petrylak, D.P.; Bellmunt, J.; Necchi, A.; Gajate, P.; Morales-Barrera, R.; Lee, J.-L.; Heijden, M.S.V.D.; Rosenbaum, E.; Penel, N.; Pang, S.-T.; et al. FORT-I: Phase II/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1/3 mRNA expression. *J. Clin. Oncol.* 2020, 38, 489. [CrossRef]

58. Rosenberg, J.E.; Gajate, P.; Morales-Barrera, R.; Lee, J.-L.; Necchi, A.; Penel, N.; Zagunel, V.; Sierlecki, M.R.; Bao, W.; Zhou, Y.; et al. Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study. *J. Clin. Oncol.* 2021, 39, 4521. [CrossRef]

59. Pal, S.K.; Rosenberg, J.E.; Hoffman-Censits, J.H.; Berger, R.; Quinn, D.I.; Galsky, M.D.; Wolf, J.; Dittrich, C.; Keam, B.; Delord, J.-P.; et al. Efficacy of BC3938, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. *Cancer Discov.* 2018, 8, 812–821. [CrossRef]

60. Liu, P.C.C.; Koblish, H.; Wu, L.; Bowman, K.; Diamond, S.; DiMatteo, D.; Zhang, Y.; Hansbury, M.; Rupar, M.; Wen, X.; et al. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptor 1, 2, and 3, displays activity against genetically defined tumor models. *PLoS ONE* 2020, 15, e0231877. [CrossRef]

61. Necchi, A.; Pouesseld, D.; Leibowitz-Amit, R.; Flechon, A.; Gupta, S.; Barthelemy, P.; Maio, M.; Zhu, X.; Asatiani, E.; Serbest, G.; et al. Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA). *Ann. Oncol.* 2018, 29, viii319–viii320. [CrossRef]

62. Hall, T.G.; Yu, Y.; Eathiraj, S.; Wang, Y.; Savage, R.E.; Lapiere, J.-M.; Schwartz, B.; Abbadessa, G. Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting Urothelial FGFR Dysregulation. *PLoS ONE* 2016, 11, e0162594. [CrossRef]

63. Gavine, P.R.; Mooney, L.; Kilgour, E.; Thomas, A.P.; Al-Kadhimi, K.; Beck, S.; Rooney, C.; Coleman, T.; Baker, D.; Mellor, M.J.; et al. AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor family. *Nat. Med.* 2019, 25, 793–801. [CrossRef] [PubMed]

64. Powles, T.; Carroll, D.; Chowdhury, S.; Gravis, G.; Joly, F.; Carles, J.; Fléchon, A.; Maroto, P.; Petrylak, D.; Rolland, F.; et al. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. *Nat. Med.* 2021, 27, 793–801. [CrossRef] [PubMed]

65. Bellmunt, J.; Picos, J.; Kohli, M.; Arriaga, Y.E.; Milowsky, M.I.; Currie, G.; Abella, S.; Pal, S.K. FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUC). *J. Clin. Oncol.* 2018, 36, 4534. [CrossRef]

66. Siefker-Radtke, A.O.; Currie, A.; Abella, E.; Vaena, D.A.; Kalebasty, A.R.; Curigliano, G.; Tupikowski, K.; Andric, Z.G.; Lugowska, I.; Kelly, W.K. FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis. *J. Clin. Oncol.* 2019, 37, 4511. [CrossRef]

67. Ferguson, K.M.; Berger, M.B.; Mendrola, J.M.; Cho, H.S.; Leahy, D.J.; Lemmon, M.A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. *Mol. Cell* 2003, 11, 507–517. [CrossRef]

68. Olayioye, M.A.; Neve, R.M.; Lane, H.A.; Hynes, N.E. The ErbB signaling network: Receptor heterodimerization in development and cancer. *Embo J.* 2000, 19, 3159–3167. [CrossRef]

69. Carpenter, G. ErbB-4: Mechanism of action and biology. *Exp. Cell Res.* 2003, 284, 66–77. [CrossRef]

70. Citri, A.; Skaria, K.B.; Yarden, Y. The deaf and the dumb: The biology of ErbB-2 and ErbB-3. *Exp. Cell Res.* 2003, 284, 54–65. [CrossRef]

71. Soltis, S.P.; Cantley, L.C. p120ctbl is a cytosolic adapt.pter protein that associates with phosphoinositide 3-kinase in response to epidermal growth factor in PC12 and other cells. *J. Biol. Chem.* 1996, 271, 563–567. [CrossRef]

72. Eriksson, P.; Sjödahl, G.; Chebil, G.; Liedberg, F.; Höglund, M. HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts. *Oncotarget* 2017, 8, 48905–48914. [CrossRef]

73. Zhang, H.; Berezov, A.; Wang, Q.; Zhang, G.; Drebin, J.; Murrali, R.; Greene, M.I. ErbB receptors: From oncogenes to targeted cancer therapies. *J. Clin. Invest.* 2007, 117, 2051–2058. [CrossRef] [PubMed]
74. Jeruss, J.S.; Liu, N.X.; Chung, Y.; Magrane, G.; Waldman, F.; Edgerton, S.; Yang, X.; Thor, A.D. Characterization and chromosomal instability of novel derived cell lines from a wt-erbB-2 transgenic mouse model. *Carcinogenesis* 2003, 24, 659–664. [CrossRef] [PubMed]

75. Miller, K.; Morant, R.; Stenzl, A.; Zuna, I.; Wirth, M. A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium. *Urol. Int.* 2016, 96, 5–13. [CrossRef] [PubMed]

76. Hussain, M.; Daignault, S.; Agarwal, N.; Grivas, P.D.; Sieffker-Radtke, A.O.; Puzanov, I.; MacVicar, G.R.; Levine, E.G.; Srinivas, S.; Twardowski, P.; et al. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. *Cancer* 2014, 120, 2684–2693. [CrossRef] [PubMed]

77. Oudard, S.; Culine, S.; Vano, Y.; Goldwasser, F.; Théodore, C.; Nguyen, T.; Voog, E.; Banu, E.; Vieillefond, A.; Priou, F.; et al. Multicentre randomised phase II trial of gemcitabine–platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. *Eur. J. Cancer* 2015, 51, 45–54. [CrossRef]

78. Bryce, A.H.; Kurzrock, R.; Meric-Bernstam, F.; Hurwitz, H.; Hainsworth, J.D.; Spigel, D.R.; Bose, R.; Swanton, C.; Burris, H.A.; Guo, S.; et al. Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway. *J. Clin. Oncol.* 2017, 35, 348. [CrossRef]

79. Powles, T.; Huddart, R.A.; Elliott, T.; Sarker, S.J.; Ackerman, C.; Jones, R.; Hussain, S.; Crabb, S.; Jagdev, S.; Chester, J.; et al. Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer. *J. Clin. Oncol.* 2017, 35, 48–55. [CrossRef]

80. Kiss, B.; Wyatt, A.W.; Douglas, J.; Skuginna, V.; Mo, F.; Anderson, S.; Rotzer, D.; Fleischmann, A.; Genitsch, V.; Hayashi, T.; et al. Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. *Sci. Rep.* 2017, 7, 42713. [CrossRef]

81. Galsky, M.D.; Del Conte, G.; Foti, S.; Yu, E.Y.; Machiels, J.-P.H.; Doger, B.; Necchi, A.; De Braud, F.G.; Hamilton, E.P.; Hennesquin, A.; et al. Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC). *J. Clin. Oncol.* 2022, 40, 438. [CrossRef]

82. Zhou, L.; Xu, H.; Li, S.; Yan, X.; Li, J.; Wu, X.; Chi, Z.; Si, L.; Cui, C.; Kong, Y.; et al. Study RC48-C014: Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma. *J. Clin. Oncol.* 2022, 40, 515. [CrossRef]

83. Ching, C.B.; Hansel, D.E. Expanding therapeutic targets in bladder cancer: The PI3K/Akt/mTOR pathway. *Lab. Investig.* 2010, 90, 1406–1414. [CrossRef] [PubMed]

84. Schmelze, T.; Hall, M.N. TOR, a Central Controller of Cell Growth. *Cell* 2000, 103, 253–262. [CrossRef]

85. Hynes, N.E.; MacDonald, G. ErbB receptors and signaling pathways in cancer. *Curr. Opin. Cell Biol.* 2009, 21, 177–184. [CrossRef]

86. Xie, Y.; Su, N.; Yang, J.; Tan, Q.; Huang, S.; Jin, M.; Ni, Z.; Zhang, B.; Zhang, D.; Luo, F.; et al. FGFR signaling in health and disease. *Signal. Transduct. Target. Ther.* 2020, 5, 1–38. [CrossRef]

87. Fruman, D.A.; Chiu, H.; Hopkins, B.D.; Bagrodia, S.; Cantley, L.C.; Abraham, R.T. The PI3K Pathway in Human Disease. *Cell* 2017, 170, 605–635. [CrossRef] [PubMed]

88. Maehama, T.; Dixon, J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol-3,4,5-trisphosphate. *J. Biol. Chem.* 1998, 273, 13375–13378. [CrossRef] [PubMed]

89. Gildea, J.J.; Herlevsen, M.; Harding, M.A.; Gulding, K.M.; Moskaluk, C.A.; Frierson, H.F.; Theodorescu, D. PTEN can inhibit activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer. *J. Immunother. Cancer* 2021, 9. [CrossRef] [PubMed]
Cancers 2022, 14, 1795

97. Ma, L.; Chen, Z.; Erdjument-Bromage, H.; Tempst, P.; Pandolfi, P.P. Phosphorylation and functional activation of TSC2 by Erk implicates for tuberous sclerosis and cancer pathogenesis. Cell 2005, 121, 179–193. [CrossRef]

98. Mendoza, M.C.; Er, E.E.; Blenis, J. The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends Biochem. Sci. 2011, 36, 320–328. [CrossRef]

99. Nawroth, R.; Stellwagen, F.; Schulz, W.A.; Stoehr, R.; Hartmann, A.; Krause, B.J.; Gschwendt, J.E.; Retz, M. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS ONE 2011, 6, e27509. [CrossRef]

100. She, Q.B.; Halilovic, E.; Ye, Q.; Zhen, W.; Shirasawa, S.; Sasazuki, T.; Solit, D.B.; Rosen, N. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010, 18, 39–51. [CrossRef]

101. Nazarian, R.; Shi, H.; Wang, Q.; Kong, X.; Koya, R.C.; Lee, H.; Chen, Z.; Lee, M.K.; Attar, N.; Szegar, H.; et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468, 973–977. [CrossRef]

102. Chandarlapaty, S.; Sawai, A.; Scaltriti, M.; Rodrik-Outlet, V.; Grbovic-Huezo, O.; Serra, V.; Majumder, P.K.; Baselga, J.; McPherson, V.; Reardon, B.; Bhayankara, A.; Scott, S.N.; Boyd, M.E.; Garcia-Grossman, I.R.; Regazzi, A.M.; McCoy, A.S.; Kim, D.M. mTOR and cancer: Insights into a complex relationship. Nat. Rev. Cancer 2020, 20, 58–71. [CrossRef]

103. Bendell, J.C.; Rodon, J.; Burris, H.A.; de Jonge, M.; Verweij, J.; Birle, D.; Demanse, D.; De Buck, S.S.; Ru, Q.C.; Peters, M.; et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 2012, 30, 292–290. [CrossRef] [PubMed]

104. McPherson, V.; Reardon, B.; Bhayankara, A.; Scott, S.N.; Boyd, M.E.; Garcia-Grossman, I.R.; Regazzi, A.M.; McCoy, A.S.; Kim, P.H.; Al-Ahmadie, H.; et al. A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. Cancer 2020, 126, 4532–4544. [CrossRef] [PubMed]

105. Xing, Y.; Lin, N.U.; Maurer, M.A.; Chen, H.; Mahvash, A.; Sahin, A.; Akcakanat, A.; Li, Y.; Abramson, V.; Litton, J.; et al. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PI3KCA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019, 21, 78. [CrossRef] [PubMed]

106. Sun, D.; Sawada, A.; Nakashima, M.; Kobayashi, T.; Ogawa, O.; Matsui, Y. MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway. Urol. Oncol. 2015, 33, 111.e117–126. [CrossRef] [PubMed]

107. Panwalkar, A.; Versiovske, S.; Giles, F.J. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004, 100, 657–666. [CrossRef]

108. Sabatini, D.M. mTOR and cancer: Insights into a complex relationship. Nat. Rev. Cancer 2006, 6, 729–734. [CrossRef]

109. Hudes, G.; Carducci, M.; Tomczak, P.; Dutcher, J.; Figlin, R.; Kapoor, A.; Staroslawska, E.; Sosman, J.; McDermott, D.; Bodrogi, I.; et al. Phase II study of everolimus in patients with platinum-resistant metastatic urothelial carcinoma. N. Engl. J. Med. 2007, 356, 2271–2281. [CrossRef]

110. Yoo, J.C.; Shah, M.H.; Ito, T.; Bohus, C.L.; Wolin, E.M.; Van Cutsem, E.; Hobday, T.J.; Okusaka, T.; Capdevila, J.; de Vries, E.G.; et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 2011, 364, 514–523. [CrossRef]

111. Mansure, J.J.; Nissim, R.; Chevailler, S.; Rocha, J.; Scarlata, E.; Kassouf, W. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol. 2009, 8, 2339–2347. [CrossRef]

112. Milowsky, M.I.; Iyer, G.; Regazzi, A.M.; Al-Ahmadie, H.; Gerst, S.R.; Ostroumova, L.; Gellert, L.L.; Kaplan, R.; Garcia-Grossman, I.R.; Pendse, D.; et al. Phase II Study of everolimus in metastatic urothelial cancer. BJU Int. 2013, 112, 462–470. [CrossRef]

113. Iyer, G.; Hanrahan, A.J.; Milowsky, M.I.; Al-Ahmadie, H.; Scott, S.N.; Janakiraman, M.; Pirun, M.; Sander, C.; Socci, N.D.; Ostroumova, L.; et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012, 338, 221. [CrossRef] [PubMed]

114. Seront, E.; Rottey, S.; Sautois, B.; Kerger, J.; D’Hondt, L.A.; Verschaeve, V.; Dopchie, C.; Vandenbulcke, J.M.; Whenham, N.; et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: Clinical activity, molecular response, and biomarkers. Ann. Oncol. 2012, 23, 2663–2670. [CrossRef] [PubMed]

115. Seront, E.; Pinto, A.; Bouzin, C.; Bertrand, L.; Machiels, J.P.; Feron, O. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation. Br. J. Cancer 2013, 109, 1586–1592. [CrossRef] [PubMed]

116. Faes, S.; Demartines, N.; Dormond, O. Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity. Oxid. Med. Cell Longev. 2017, 2017, 1726078. [CrossRef] [PubMed]

117. Niekisch, G.; Retz, M.; Thalgott, M.; Balabanov, S.; Honecker, F.; Ohlmann, C.H.; Stöckle, M.; Bögemann, M.; Vom Dorp, F.; Gschwendt, J.E.; et al. Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09). Oncology 2015, 89, 70–78. [CrossRef]

118. Adib, E.; Klonowska, K.; Giannikou, K.; Do, K.T.; Pruitt-Thompson, S.; Bhushan, K.; Milstein, M.I.; Hedglin, J.; Kargus, K.E.; Sholl, L.M.; et al. Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. Clin. Cancer Res. 2021, 27, 3845–3853. [CrossRef]

119. Pulido, M.; Roubaud, G.; Cazeau, A.L.; Mahammedi, H.; Vedrine, L.; Joly, F.; Mourey, L.; Pfister, C.; Gobena, A.; Lortal, B.; et al. Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer. BMC Cancer 2018, 18, 194. [CrossRef]

120. Gerullis, H.; Eimer, C.; Ecke, T.H.; Georgas, E.; Freitas, C.; Kastenholz, S.; Arndt, C.; Heusch, C.; Otto, T. A Phase II trial of temsirolimus in second-line metastatic urothelial cancer. Med. Oncol. 2012, 29, 2870–2876. [CrossRef]

121. Voss, M.H.; Gordon, M.S.; Mita, M.; Rini, B.; Makker, V.; Macarulla, T.; Smith, D.C.; Cervantes, A.; Puzanov, I.; Pili, R.; et al. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. Br. J. Cancer 2020, 123, 1590–1598. [CrossRef]
163. Cochin, V.; Gross-Goupil, M.; Ravaud, A.; Godbert, Y.; Le Moulec, S. Cabozantinib: Mechanism of action, efficacy and indications. Bull. Cancer 2017, 104, 393–401. [CrossRef] [PubMed]

164. Dolan, M.; Mastri, M.; Tracz, A.; Christensen, J.G.; Chatta, G.; Ebos, J.M.L. Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance. PloS ONE 2019, 14, e0220101. [CrossRef] [PubMed]

165. Apolo, A.B.; Nadal, R.; Tomita, Y.; D avarpanah, N.N.; Cordes, L.M.; Steinberg, S.M.; Cao, L.; Parnes, H.L.; Costello, R.; Merino, M.J.; et al. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: An open-label, single-centre, phase 2 trial. Lancet Oncol. 2020, 21, 1099–1109. [CrossRef]

166. Loriot, Y.; Grivas, P.; De Wit, R.; Bal ar, A.V.; Siefker-Rad tke, A.O.; Zoln ierek, J.; C soszi, T.; Shin, S.J.; Park, S.H.; At duev, V.; et al. First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study. J. Clin. Oncol. 2022, 40, 432. [CrossRef]

167. Jin, Y.; Xu, Z.; Yan, H.; He, Q.; Yang, X.; Luo, P. A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors. Front. Pharm. 2020, 11, 891. [CrossRef] [PubMed]

168. Shah, R.R.; Morganroth, J. Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit. Drug Saf. 2015, 38, 693–710. [CrossRef]

169. Pal, S.K.; Frankel, P.H.; Mortazavi, A.; Milowsky, M.; Vaishampayan, U.; Parikh, M.; Ly ou, Y.; Weng, P.; Parikh, R.; Teply, B.; et al. Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021, 7, 1536–1543. [CrossRef]

170. Hahn, W.C.; Bader, J.S.; Braun, T.P.; Califano, A.; Clemons, P.A.; Druker, B.J.; Ewald, A.J.; Fu, H.; Jagu, S.; Kemp, C.J.; et al. An expanded universe of cancer targets. Cell 2021, 184, 1142–1155. [CrossRef]

171. Hanahan, D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022, 12, 31–46. [CrossRef]

172. Meeks, J.J.; Al-Ahmadie, H.; Faltas, B.M.; Taylor, J.A., 3rd; Flaig, T.W.; DeGraff, D.J.; Christensen, E.; Woolbright, B.L.; McConkey, D.J.; Dy rskjøt, L. Genomic heterogeneity in bladder cancer: Challenges and possible solutions to improve outcomes. Nat. Rev. Urol. 2020, 17, 259–270. [CrossRef]